ArticleInterventional pain medicine2026
Early pain-response trajectories after basivertebral nerve ablation and their relationship to 12-month clinical outcomes.
Article in Interventional pain medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Basivertebral nerve ablation (BVNA) is an established treatment for vertebrogenic low back pain, but the relationship between early post-procedural response and longer-term outcomes remains unclear. Objective: To evaluate whether early pain-response trajectories following BVNA were associated with 12-month clinical outcomes and to identify a clinically useful time point for reassessment. Methods: This prospective multicenter observational cohort study included 140 patients with MRI-confirmed Modic type 1 or 2 changes treated with BVNA between April 2024 and April 2025. Patients reported weekly percent pain relief through 8 weeks, followed by assessments at 3, 6, and 12 months. The primary outcome was ≥50% pain relief at 12 months. Discriminative performance of Week 3 and Week 6 responses was assessed using sensitivity, specificity, likelihood ratios, and receiver operating characteristic analysis. Time to first ≥50% relief was evaluated using Kaplan-Meier methods. Secondary outcomes included changes in Numeric Rating Scale (NRS), Oswestry Disability Index (ODI), Patient Global Impression of Change (PGIC), and post-procedural healthcare utilization. Results: At 12 months, 82.1% achieved ≥50% pain relief. The mean NRS improved by 4.3 points and the mean ODI improved by 34 points, with 84.3% and 94.3% achieving Minimally Clinically Important Difference (MCID) thresholds, respectively. The Week 3 response was linked to increased likelihood of 12-month success (LR Conclusion: Early pain-response trajectories following BVNA were associated with 12-month outcomes. Clinically meaningful submaximal improvement (≥30%) identified patients who attained durable benefit, whereas absence of early improvement was linked to a lower likelihood of long-term success. These findings suggest that meaningful response signals may emerge before conventional ≥50% responder thresholds are reached, providing a more nuanced framework for interpreting early post-procedural response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.